Germline mutations in STK11, which encodes the tumor suppressor liver kinase B1 (LKB1), promote Peutz-Jeghers syndrome (PJS), a cancer predisposition syndrome characterized by the development of gastrointestinal (GI) polyps. Here, we report that heterozygous deletion of Stk11 in T cells (LT het mice) is sufficient to promote GI polyposis. Polyps from LT het mice, Stk11 +/− mice, and human PJS patients display hallmarks of chronic inflammation, marked by inflammatory immune-cell infiltration, signal transducer and activator of transcription 3 (STAT3) activation, and increased expression of inflammatory factors associated with cancer progression [interleukin 6 (IL-6), IL-11, and CXCL2]. Targeting either T cells, IL-6, or STAT3 signaling reduced polyp growth in Stk11 +/− animals. Our results identify LKB1-mediated inflammation as a tissue-extrinsic regulator of intestinal polyposis in PJS, suggesting possible therapeutic approaches by targeting deregulated inflammation in this disease.
L iver kinase B1 (LKB1) is a multifaceted serine/threonine kinase with roles in metabolism, cell polarity, cell size control, and proliferation (1) . Somatic mutations in STK11 are associated with several human cancers, including lung cancer (where it is frequently comutated with KRAS) and gynecological cancers (ovary, uterus, and cervix) (2) . Heterozygous germline mutations in STK11 predispose both humans and mice to the development of Peutz-Jeghers syndrome (PJS) (3) (4) (5) (6) (7) , an autosomal dominant hereditary disease characterized by the development of benign gastrointestinal (GI) hamartomatous polyps (8) . PJS patients also have a high cumulative cancer risk, with >90% chance of developing tumors by age 65 (9) .
Much of our understanding of PJS development and pathogenesis has been derived from Stk11 +/− mice, which develop GI polyps histologically similar to those found in PJS patients, with an average latency of 9 to 12 months (5-7). Deletion of Stk11 in smooth-muscle cells promotes GI polyp formation with lower penetrance than that in whole-body Stk11 +/− mice (~60% versus 85 to 100%) (10) . We used a VillinCre transgene to delete Stk11 in intestinal epithelial cells (IECs) of the small intestine and colon. We found no evidence of GI polyps in mice heterozygous (Stk11 fl/+ ;Villin-Cre) for Stk11 in IECs, even those >52 weeks of age (table S1), which argues for additional nonepithelial functions for LKB1 that contribute to disease development in Stk11 +/− mice and PJS patients. LKB1 plays an essential role in regulating hematopoietic stem-cell metabolism and survival (11) (12) (13) . Unexpectedly, we found that aged mice (>52 weeks) with heterozygous deletion of Stk11 throughout the hematopoietic system (LH het : Stk11 fl/+ ;Vav-iCre) developed GI polyps at the junction of the small intestine and stomach reminiscent of PJS polyps (Fig. 1A) . Polyps observed in LH het mice displayed an arborizing smooth-muscle core and were histologically indistinguishable from polyps observed in Stk11 +/− mice (Fig. 1A) . We next generated mice harboring heterozygous or homozygous Stk11 mutations in either the T cell (LT ; Cd19-Cre) compartments. LT het mice developed GI polyps at an incidence similar to that of LH het mice, and homozygous deletion of Stk11 in T cells (LT ko ) doubled the incidence of polyp formation (Fig. 1, B Fig. 2A and fig. S3A ). T cells (CD4 + and CD8 + ), macrophages, and neutrophils were diffusely present throughout the polyps, with lymphocytes also organizing into concentrated centers in the smooth-muscle core of the polyps ( Fig. 2A and fig. S3 , A to C). Histological analysis of polyps from two independent, unrelated PJS patients revealed clustering of T cells in the smooth-muscle core and stroma of the polyps (Fig. 2B) , similar to our observations in mouse samples. To assess the impact of lymphocytes on disease progression, we crossed Stk11 +/− mice onto a Rag2-deficient background (which lack mature lymphocytes because of a block in development). Although Stk11
−/− mice still developed polyps, polyp size was significantly decreased in Stk11 +/− mice lacking lymphocytes (Fig. 2, C and D) .
We next assessed inflammatory cytokine expression in polyps and adjacent nonpolyp tissue from aged control and LT het animals (>52 weeks of age) (Fig. 2E) . Polyps from diseased LT het mice consistently expressed increased levels of inflammatory cytokines-including Il1b, Il6, Il11, and Tnfa-compared with GI sections from control animals or LT het mice that did not develop disease (Fig. 2E) . Notable in this profile were high levels of Il6 and Il11, cytokines that are associated with chronic gastric inflammation and GI tumor development (16) (17) (18) . Similar changes in inflammatory cytokine gene expression were observed in polyps from Stk11 +/− mice (Fig. 2F ). Gr1 mid ) and neutrophils (CD11b + Gr1 hi ) in polyps of mice heterozygous for LKB1 in T cells (Fig. 2I) .
To test whether inflammation could influence PJS polyp formation, we subjected young control and Stk11 +/− mice to sublethal irradiation [4.5 grays (Gy)], which stimulates acute mucositis and inflammatory cytokine production in the GI tract (19) . All Stk11 +/− mice that received radiation developed polyps within 16 weeks of treatment, whereas age-matched nonirradiated Stk11 +/− mice did not develop visible polyps during this time ( + and CD8 + T cells activated under nonpolarizing conditions displayed increased secretion of many of the inflammatory factors observed in PJS polyps, including CXCL2, CXCL9, and interleukin 6 (IL-6) (Fig. 3, A and B) . The activation of naïve LT het or LT ko CD4 + T cells led to the increased generation of interferon-g (IFN-g)-and IL-17A-producing CD4 + T cells under T helper 1 (T H 1)-and T H 17-polarizing conditions, respectively (Fig. 3 , C to E). LKB1-deficient T H 17 cells also displayed increased IL-6 and tumor necrosis factor-a (TNF-a) production (Fig. 3 , E and F).
LKB1 deletion in T cells leads to deregulated metabolism and increased IFN-g production by CD4
+ and CD8 + T cells (20 S9, C and D) .
We next tested whether Stk11-mutant T cells could modulate inflammation in surrounding tissues. Supernatants from Stk11 mutant T cells stimulated a fourfold increase in Il6 expression in nontransformed mouse embryonic fibroblasts (MEFs) compared with supernatants from wildtype T cells (Fig. 3I) . Stk11 −/− MEFs secreted IL-6 in the absence of inflammatory stimuli and produced significantly more CXCL2 and IL-6 when stimulated with lipopolysaccharide (LPS) (Fig. 3J  and fig. S10A ). Deregulated IL-6 production by Stk1 −/− MEFs was not limited to LPS treatment because other Toll-like receptor (TLR) ligands strongly induced IL-6 production in LKB1-deficient MEFs (Fig. 3J ). IL-6 production by LKB1-deficient MEFs was insensitive to mTORC1 inhibition by use of rapamycin ( fig. S10B ). Thus, in addition to aberrant immune-cell function, Stk11 mutations in nonimmune tissues (epithelial and/or stromal cells) in PJS patients may confer increased responsiveness to inflammatory stimuli.
In inflammation-driven cancers such as gastric and colon cancer, tumor progression is driven by chronic STAT3 activation downstream of inflammatory cytokines such as IL-6 and IL-11 (21) . Consistent with the abundance of STAT3-activating cytokines in the GI microenvironment, polyps from LT het , LT ko , and Stk11 +/− mice displayed elevated phospho-STAT3 (Y705) staining compared with similar sections from LT wt and Stk11 +/+ mice (Fig. 4A) . A similar distribution of phospho-STAT3 (Y705) staining was observed in the stromal compartment of polyps from PJS patients (Fig. 4B) . Both polyps and adjacent nonpolyp tissue from diseased mice exhibited increased STAT3 phosphorylation compared with that of nondiseased tissue from control mice (Fig. 4, C and D) . Expression of several STAT3 target genes, including Ccnd1 and Socs3, was increased in polyps ( Fig. 4E and fig. S11A ). Additionally, the STAT3 target gene Tlr2, which encodes a pattern-recognition receptor potentiating inflammatory responses to bacterial peptidoglycans, was significantly increased in the polyps of LT het and Stk11 +/− mice (Fig. 4F) . Increased TLR2 expression and polymorphisms in the TLR2 gene are associated with gastric cancer (22, 23) . WT ND NP P LThet:
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WT NP P Stk11: sufficient to stimulate STAT3 phosphorylation ( Fig. 4G ) and promote increased expression of a subset of STAT3 target genes, including Tlr2, in nontransformed MEFs (Fig. 4H and  fig. S11B ). Last, we assessed the contribution of IL-6-STAT3 signaling to PJS polyp growth. GI polyp size was significantly reduced in Stk11 +/− mice lacking IL-6 expression (Fig. 4, I and J), similar to that observed in lymphocyte-deficient Stk11 +/− mice (Fig. 2, C and D) . Polyps from Stk11 fig. S11C ), suggesting that other STAT3-activating factors such as IL-11 may be active in these tissues. Last, we inhibited STAT3 signaling in Stk11 +/− mice in vivo using the JAK2 inhibitor AZD1480 (24, 25) . AZD1480-treated Stk11 +/− mice displayed significant reductions in polyp size compared with that of controls (Fig. 4 , K and L). AZD1480 treatment reduced phospho-STAT3 levels and immune cell infiltration in GI tissues of Stk11 +/− mice ( Fig. 4M and fig. S12 , A and B), whereas mTORC1 activity was unaffected ( fig. S12A) . Thus, the blockade of STAT3 signaling can affect polyp development in this PJS mouse model.
The development of hamartomatous polyps in PJS patients has been attributed to cell-intrinsic tumor suppressor functions for Stk11 in epithelial and/or stromal tissue cells in the GI tract. Our findings establish immune-mediated inflammation as a hallmark of PJS disease and highlight a critical role for Stk11 mutant T cells in PJS disease progression. Our data argue for a more complex role for Stk11 mutations in PJS disease development, with deregulated inflammatory responses by LKB1 mutant immune cells, in addition to epithelial and stromal tissues (26) , reinforcing tumor inflammation and chronic STAT3 activation to drive polyp growth. Consistent with this, elevated IL-6 levels have been observed in LKB1-deficient tumors (27) . Our data raise the possibility that inflammatory events in the GI tract (pathogen interactions with Stk11 +/− immune cells) may trigger the inflammation we have found associated with PJS polyps in mice and humans to stimulate intestinal polyposis. Targeting chronic GI inflammation may present a novel approach to reducing disease incidence and polyp burden in PJS patients.
